Talphera, Inc. (NasdaqCM: TLPH)
Health Care · Pharmaceuticals · US
$1.19
0.00% today · +107.1% 1Y
Talphera, Inc. (NasdaqCM: TLPH) operates in the Pharmaceuticals industry within the Health Care sector. The company is valued at $61.77M and employs 12 people.
Over the last twelve months the share price has gained 107.1%, trading between 0.47 and 1.57.
Tweenvest scores Talphera, Inc. across four factors: quality 27/100. Its strongest factor is quality.
TLPH price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $61.77M
- Revenue (TTM)
- $1.00K
- P/E
- —
- EPS
- -0.24
- Dividend yield
- —
- Beta (5Y)
- 0.70
- 52-week high
- $1.57
- 52-week low
- $0.47
- Avg volume (3M)
- —
- Shares outstanding
- 51.91M
- Employees
- 12
- Next earnings
- —
About Talphera, Inc.
Talphera, Inc. is a specialty pharmaceutical company focused on developing and commercializing therapeutic products intended for use in carefully monitored medical environments. Their lead experimental candidate is Niyad, a lyophilized (freeze-dried) formulation of nafamostat. This anticoagulant is currently being assessed under an investigational device exemption for its application in extracorporeal circuits. The company's development pipeline also features LTX-608, a potential anti-inflammatory and antiviral agent being explored for the treatment of numerous conditions, including COVID-19, disseminated intravascular coagulation (DIC), acute respiratory distress syndrome (ARDS), and acute pancreatitis. Furthermore, Talphera is advancing Fedsyra, a pre-filled syringe containing ephedrine, and PFS-02, a pre-filled syringe containing phenylephrine. Established in 2005, the company was previously known as AcelRx Pharmaceuticals, Inc. It adopted the name Talphera, Inc. in January 2024 and maintains its corporate headquarters in San Mateo, California.
- ISIN
- US00444T2096
- Founded
- 2005
- Listed since
- Feb 11, 2011
- Exchange
- Nasdaq Capital Market
- Currency
- USD
Other Pharmaceuticals companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Eli Lilly and CompanyNYSE: LLY | $1.11T | $1,251.05 | +0.33% |
| Johnson & JohnsonNYSE: JNJ | $658.00B | $270.67 | -0.87% |
| Merck & Co., Inc.NYSE: MRK | $371.70B | $152.72 | +1.37% |
| Roche Holding AGSWX: ROP | $368.80B | CHF370.70 | +0.08% |
| Novartis AGSWX: NOVN | $300.52B | CHF126.76 | -0.52% |
| AstraZeneca PLCLSE: AZN | $256.25B | £122.08 | +0.81% |
| Novo Nordisk A/SCPSE: NOVO B | $206.64B | Dkr299.25 | -0.53% |
| Pfizer Inc.NYSE: PFE | $159.42B | $27.93 | -0.14% |
Figures last refreshed Aug 18, 2026.